Amylyx Pharmaceuticals, Inc.
AMLXNASDAQHealthcare● Active
$13.01
$-0.31(-2.33%)
Market Cap$1.1B
P/E Ratio—
52W High$18.605
52W Low$4.76
Amylyx Pharmaceuticals, Inc. (AMLX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMLX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.09B | $0.38B | $0.02B | $0.00B |
| Cost of Revenue | $0.00B | $0.04B | $0.03B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.05B | $0.36B | $0.02B | $0.00B |
| Gross Margin %(computed) | — | 51.75% | 93.32% | 86.54% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.09B | $0.10B | $0.13B | $0.09B | $0.04B |
| G&A Expenses | $0.00B | $0.11B | $0.18B | $0.12B | $0.04B |
| Total Operating Expenses | $0.15B | $0.36B | $0.32B | $0.22B | $0.08B |
| Operating Income | ($0.15B) | ($0.31B) | $0.04B | ($0.20B) | ($0.08B) |
| Operating Margin %(computed) | — | -360.22% | 10.19% | -905.72% | — |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.14B) | ($0.30B) | $0.05B | ($0.20B) | ($0.09B) |
| Income Tax Expense | $0.00B | ($0.00B) | $0.01B | $0.00B | $0.00B |
| Net Income | ($0.14B) | ($0.30B) | $0.05B | ($0.20B) | ($0.09B) |
| Net Margin %(computed) | — | -345.36% | 12.94% | -892.38% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.53 | $-4.43 | $0.73 | $-2.98 | $-1.52 |
| Wtd Avg Shares | 0.09B | 0.07B | 0.07B | 0.07B | 0.06B |
| EBITDA | ($0.14B) | ($0.29B) | $0.04B | ($0.20B) | ($0.08B) |
| EBITDA Margin %(computed) | — | -333.03% | 10.48% | -903.53% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Amylyx Pharmaceuticals, Inc. data
About Amylyx Pharmaceuticals, Inc. (AMLX) Income Statement
Amylyx Pharmaceuticals, Inc. (AMLX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AMLX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.14B) — a net profit margin of —.
Frequently asked questions
AMLX · 4 questionsAmylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
AMLX revenueAMLX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08